A Futuristic concept of understanding Biosimilars in the Pharmaceutical Field

Mohammed Shakir Ghouse; Mohd Abdul Mugni Danish

doi:10.37591/(rrjops).v14i3.1353

Abstract

Biosimilars, which are highly similar versions of approved biologic drugs, are expected to continue their expansion into new therapeutic areas, offering cost-effective alternatives to a wider range of medical conditions. This evolution includes the development of next-generation biosimilars with improved properties, such as enhanced efficacy, safety, and patient convenience. Innovations in drug delivery methods, reduced immunogenicity, and personalized medicine are anticipated to drive the development of biosimilars tailored to individual patient characteristics. Regulatory agencies are refining the approval pathways for biosimilars, aiming for greater clarity and consistency, while interchangeability designations will enhance their adoption. Educational efforts targeting healthcare professionals, patients, and policymakers will build confidence in biosimilars and promote their wider use. Collaboration between biosimilar manufacturers, biopharmaceutical companies, and academic institutions will drive innovation, leading to improved biosimilar products and manufacturing processes. Additionally, the growing role of emerging markets and global regulatory harmonization will further facilitate access to biosimilars worldwide. The biosimilar field's continual evolution promises to enhance patient access to biologic therapies and improve treatment outcomes while contributing to the sustainability of healthcare systems.

Abstract

Keywords